

References

I-9285

1. National Hemophilia Foundation. Bleeding Disorders A-Z/Types/Hemophilia B. Accessed at: <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-b>.
2. Srivastave A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd edition. August 2020.
3. Medical and Scientific Advisory Committee. MASAC recommendation regarding doses of clotting factor concentrate in the home. MASAC Document #242. June 2016.
4. Medical and Scientific Advisory Council (MASAC) MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Document #280. August 2023.
5. Medical and Scientific Advisory Committee. MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without inhibitors. MASAC Document #267. April 2022.
6. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med 2020; 382:29-40.
7. Medical and Scientific Advisory Committee. MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia. Document #254. December 2018.
8. Pipe Steven, VandenDriessche T, Pasi J, Miesbach W. Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy. Medscape Education Series. Presented through a collaboration between the National Hemophilia Foundation and Medscape. December 2019. Accessed at <https://www.medscape.org/viewarticle/922905>
9. World Health Organization (WHO) Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. 2016 update.
10. World Health Organization (WHO) Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach – Second edition. June 2016.
11. ICER Institute for Clinical and Economic Review. Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A: Effectiveness and Value. Draft Evidence Report. September 13, 2022.
12. HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients. Accessed at HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients - Full Text View - ClinicalTrials.gov
13. BEQVEZ prescribing information. Pfizer Inc. April 2024.